These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 32519591

  • 1. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K, Silva Miguel L, Hillas G, Borges M, Papageorgiou G, Viana D, Malhadeiro J, Soulard S.
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [No Abstract] [Full Text] [Related]

  • 2. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV, Leader S, Plauschinat C, Raparla S, Yan M, Ye X, Young D.
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [Abstract] [Full Text] [Related]

  • 3. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A, Huerta A, Navarro Artieda R, Monsó E, Landis SH, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [Abstract] [Full Text] [Related]

  • 4. Comparing Costs and Healthcare Resource Utilization (HCRU) Using LAMA versus LABA/ICS at Treatment Initiation for COPD: Findings from CITRUS (Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea) Study.
    Choi KY, Kim HI, Rhee CK, Yoo KH, Park YB, Kim Y, Lee SE, Kim JA, Hwang YI.
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1661-1671. PubMed ID: 39050737
    [Abstract] [Full Text] [Related]

  • 5. Switching treatments in COPD: implications for costs and treatment adherence.
    Braido F, Lavorini F, Blasi F, Baiardini I, Canonica GW.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2601-8. PubMed ID: 26664108
    [Abstract] [Full Text] [Related]

  • 6. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
    Tsai YH, Yang TM, Lin CM, Huang SY, Wen YW.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
    [Abstract] [Full Text] [Related]

  • 7. Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice.
    Fens T, van der Pol S, Kocks JWH, Postma MJ, van Boven JFM.
    Value Health; 2019 Oct; 22(10):1092-1101. PubMed ID: 31563251
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct; 12():997-1008. PubMed ID: 28392684
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.
    Int J Chron Obstruct Pulmon Dis; 2012 Oct; 7():183-99. PubMed ID: 22500119
    [Abstract] [Full Text] [Related]

  • 10. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada.
    Tavakoli H, Johnson KM, FitzGerald JM, Sin DD, Gershon AS, Kendzerska T, Sadatsafavi M.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct; 14():2003-2013. PubMed ID: 31564848
    [Abstract] [Full Text] [Related]

  • 11. Trend of cost and utilization of COPD medication in Korea.
    Lee J, Lee JH, Kim JA, Rhee CK.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct; 12():27-33. PubMed ID: 28031708
    [Abstract] [Full Text] [Related]

  • 12. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS, Landis SH, Wurst K, Le H.
    Respir Res; 2015 Nov 16; 16():141. PubMed ID: 26572740
    [Abstract] [Full Text] [Related]

  • 13. Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study.
    Roggeri A, Micheletto C, Roggeri DP.
    Int J Chron Obstruct Pulmon Dis; 2014 Nov 16; 9():569-76. PubMed ID: 24940053
    [Abstract] [Full Text] [Related]

  • 14. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 16; 13():1545-1556. PubMed ID: 29785104
    [Abstract] [Full Text] [Related]

  • 15. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V, Corhay JL, Germonpré P, Janssens W, Joos GF, Liistro G, Vincken W, Gurdain S, Vanvlasselaer E, Lehouck A.
    Int J Chron Obstruct Pulmon Dis; 2017 Nov 16; 12():793-801. PubMed ID: 28293106
    [Abstract] [Full Text] [Related]

  • 16. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS, DePietro M, McPheeters J, Fox KM.
    Ther Adv Respir Dis; 2018 Nov 16; 12():1753466618772750. PubMed ID: 29737943
    [Abstract] [Full Text] [Related]

  • 17. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.
    Int J Chron Obstruct Pulmon Dis; 2018 Nov 16; 13():781-792. PubMed ID: 29551894
    [Abstract] [Full Text] [Related]

  • 18. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK.
    Edwards SC, Fairbrother SE, Scowcroft A, Chiu G, Ternouth A, Lipworth BJ.
    Int J Chron Obstruct Pulmon Dis; 2016 Nov 16; 11():2851-2858. PubMed ID: 27920512
    [Abstract] [Full Text] [Related]

  • 19. Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.
    van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, Rutten-van Mölken MPMH.
    Pharmacoeconomics; 2017 Jan 16; 35(1):43-63. PubMed ID: 27592021
    [Abstract] [Full Text] [Related]

  • 20. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr 16; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.